RTW INVESTMENTS LP
Q1 2023 Form 13-F
NEW YORK, NEW YORK
CIK 0001493215
· CRD 153232
· SEC-registered investment adviser
$4.8B Reported Value Total
RTW INVESTMENTS LP reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $7,179,756,279, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $13.7B gross asset value
Hedge Fund: $13.4B · Private Equity Fund: $284.4M
Source: Form ADV filed 2026-03-30
Reported value
$4.8B
Quarter over quarter
-3.4%
Holdings
60
Top-10 concentration
55.5%
Filing Structure
Reports holdings for
- RTW MASTER FUND LTD · File #028-16671 · Q4 2014 – Q2 2023 · declared by one filing
- RTW Innovation Master Fund Ltd · File #028-19525 · Q1 2019 – Q2 2023 · declared by one filing
- RTW Venture Fund Ltd · File #028-19571 · Q2 2019 – Q2 2023 · declared by one filing
- RTW Special Purpose Fund II, LLC (not a 13F filer in our records) · File #028-19631 · Q3 2019 – Q4 2020
Key People
Form ADV owners & control persons
Roderick Tze Ian Wong
MANAGING PARTNER, CHIEF INVESTMENT OFFICER
Naveen Yalamanchi
PARTNER, PORTFOLIO MANAGER
Robert John Aurigema
PARTNER, CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2023 13F record
Q1 2023 13F filing summary
| Period of report | March 31, 2023 |
|---|---|
| Filed | May 15, 2023 |
| Form | 13F-HR |
| Reported value | $4.8B |
| Positions | 60 |
| Change in reported value | -2.0% |
| New positions | 8 |
| Exited positions | 25 |
| Position turnover | 38.8% |
| Top-10 concentration | 55.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
84 | $11.7B |
|
Q1 2026 13F
Filed May 15, 2026
|
88 | $10.0B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
91 | $10.0B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
74 | $8.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
73 | $7.0B |
|
Q1 2025 13F
Filed May 15, 2025
|
68 | $6.5B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
72 | $6.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $6.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
68 | $6.5B |
|
Q1 2024 13F
Filed May 15, 2024
|
69 | $6.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
64 | $6.4B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
67 | $4.7B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
62 | $5.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
60 | $4.8B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
77 | $4.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
85 | $4.3B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
107 | $3.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
106 | $4.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
124 | $6.8B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
120 | $6.6B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RXDX PROMETHEUS BIOSCIENCES INC | $351.2M | 7.31% |
| 2 | PTCT PTC THERAPEUTICS INC | $343.6M | 7.16% |
| 3 | ALNY ALNYLAM PHARMACEUTICALS INC | $337.2M | 7.02% |
| 4 | RCKT ROCKET PHARMACEUTICALS INC | $303.0M | 6.31% |
| 5 | IMCR IMMUNOCORE HLDGS PLC | $279.3M | 5.82% |
| 6 | MASI MASIMO CORP | $277.1M | 5.77% |
| 7 | AXSM AXSOME THERAPEUTICS INC | $233.2M | 4.86% |
| 8 | PEN PENUMBRA INC | $187.7M | 3.91% |
| 9 | ARGX ARGENX SE | $179.7M | 3.74% |
| 10 | RARE ULTRAGENYX PHARMACEUTICAL IN | $171.3M | 3.57% |
| 11 | TMO THERMO FISHER SCIENTIFIC INC | $167.3M | 3.48% |
| 12 | ESTA ESTABLISHMENT LABS HLDGS INC | $161.8M | 3.37% |
| 13 | ACAD ACADIA PHARMACEUTICALS INC C | $155.1M | 3.23% |
| 14 | NTRA NATERA INC | $145.0M | 3.02% |
| 15 | MRTX MIRATI THERAPEUTICS INC | $135.5M | 2.82% |
| 16 | CLDX CELLDEX THERAPEUTICS INC NEW | $111.0M | 2.31% |
| 17 | PTGX PROTAGONIST THERAPEUTICS INC | $105.8M | 2.2% |
| 18 | OBIO ORCHESTRA BIOMED HLDGS INC | $100.2M | 2.09% |
| 19 | RNA AVIDITY BIOSCIENCES INC | $98.0M | 2.04% |
| 20 | VCEL VERICEL CORP | $96.5M | 2.01% |
Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.